United States Patent 10,973,795: Analysis of Scope, Claims, and Landscape
Patent 10,973,795, granted on April 13, 2021, to Sandoz AG, covers pharmaceutical compositions and methods of treatment involving tacrolimus. The patent's claims address specific formulations of tacrolimus, including those with particular particle size distributions and excipient combinations, aimed at improving its efficacy and reducing variability in absorption.
What is the Core Innovation Protected by Patent 10,973,795?
The central innovation of U.S. Patent 10,973,795 lies in the development of tacrolimus formulations designed to enhance bioavailability and therapeutic outcomes. These formulations are characterized by specific physical properties and chemical compositions.
What are the Key Claims of the Patent?
The patent contains multiple claims, broadly categorized into pharmaceutical compositions and methods of use.
-
Claim 1 defines a pharmaceutical composition comprising tacrolimus, a hydrophilic polymer, and a hydrophobic excipient. The tacrolimus in this composition has a specific particle size distribution, with a D90 value not exceeding approximately 500 nm and a D50 value not exceeding approximately 200 nm. This claim focuses on the controlled particle size of the active pharmaceutical ingredient (API).
-
Claim 12 describes a pharmaceutical composition further comprising a surfactant. This claim builds upon the foundational composition by incorporating a surfactant to potentially improve solubilization and absorption.
-
Claim 15 claims a method of treating a subject with an immune-mediated disease. This method involves administering a pharmaceutical composition as defined in claim 1 or 12. The method aims to achieve a target pharmacokinetic profile, such as a maximum plasma concentration (Cmax) achieved within a specified time frame post-administration.
-
Claim 18 further specifies a method of treating a subject wherein the pharmaceutical composition comprises tacrolimus and a hydrophobic excipient, with a specific D90 and D50 particle size for the tacrolimus.
-
Claim 20 details a method of improving the pharmacokinetic profile of tacrolimus in a subject. This is achieved by administering a composition containing tacrolimus with defined particle size parameters, as well as a hydrophilic polymer and a hydrophobic excipient.
What are the Specific Technical Requirements Defined by the Claims?
The patent specifies several critical technical parameters:
What is the Patent Landscape for Tacrolimus Formulations?
The patent landscape for tacrolimus is characterized by numerous patents addressing various aspects of its formulation, delivery, and therapeutic applications. These patents reflect ongoing efforts to improve the drug's performance, address side effects, and extend market exclusivity.
Who are the Key Players in Tacrolimus Patenting?
Major pharmaceutical companies and generic manufacturers hold significant portfolios related to tacrolimus.
- Original Innovators and Marketers: Companies like Astellas Pharma Inc., the originator of Prograf®, have historically held foundational patents.
- Generic Manufacturers: Companies such as Sandoz AG, Teva Pharmaceutical Industries Ltd., and others actively file patents on new formulations, manufacturing processes, and improved delivery systems to compete in the generic market.
- Biotechnology and Specialty Pharma: Some smaller entities may also hold patents related to specific applications or novel delivery technologies for tacrolimus.
What Types of Tacrolimus Patents Exist?
The patent landscape encompasses several categories:
- Composition of Matter Patents: These are typically the strongest patents, covering the active molecule itself. Most of these foundational patents for tacrolimus have expired.
- Formulation Patents: These patents, like 10,973,795, cover specific combinations of excipients, particle sizes, amorphous forms, or other physical characteristics of the drug product. These are critical for extending market exclusivity for branded and generic drugs.
- Method of Use Patents: These patents claim new therapeutic indications for tacrolimus or improved methods of treating existing conditions with tacrolimus, often linked to specific pharmacokinetic profiles or patient populations.
- Manufacturing Process Patents: These patents protect novel or improved methods for synthesizing tacrolimus or manufacturing its drug products, potentially offering cost advantages or higher purity.
- Polymorph Patents: Patents covering specific crystalline forms (polymorphs) of tacrolimus, as different polymorphs can have varying stability, solubility, and bioavailability.
How Does Patent 10,973,795 Fit into the Broader Landscape?
Patent 10,973,795 is an example of a formulation patent. It seeks to protect a specific technical advance in how tacrolimus is delivered, focusing on particle engineering and excipient selection to achieve a more predictable and effective therapeutic effect. Such patents are strategically important for:
- Generic Competition: Generic companies often seek to develop and patent novel formulations that offer an "off-patent" version of a drug with improved characteristics, potentially creating their own market niche or challenging existing branded products.
- Life Cycle Management: Branded pharmaceutical companies may use formulation patents to extend the commercial life of their drugs beyond the expiry of the original composition of matter patents.
What are the Implications of Patent Expiries?
The expiry of earlier, foundational patents on tacrolimus has opened the door for increased generic competition. However, patents like 10,973,795, which cover newer formulations, can create new exclusivity periods, influencing the timing and nature of market entry for generic versions. Understanding the expiration dates of such formulation patents is crucial for assessing market opportunities and competitive threats.
What is the Competitive Impact and Market Potential?
The development and patenting of advanced tacrolimus formulations, as exemplified by U.S. Patent 10,973,795, aim to address limitations in existing therapies and capture market share.
What are the Potential Advantages of the Patented Formulation?
The specified particle size control and excipient combinations in patent 10,973,795 are designed to offer several advantages:
- Improved Bioavailability: Controlled particle size can enhance the dissolution rate of tacrolimus, leading to more consistent absorption into the bloodstream.
- Reduced Inter-Patient Variability: By standardizing particle size and formulation, the variability in drug absorption and blood concentrations between different patients can be reduced. This leads to more predictable therapeutic effects and potentially fewer dose adjustments.
- Enhanced Efficacy and Safety: More consistent drug exposure can improve treatment efficacy and potentially reduce the risk of adverse events associated with drug concentration spikes or troughs.
- Dosing Flexibility: Improved pharmacokinetic profiles may allow for more flexible dosing regimens.
How does this Formulation Compare to Existing Tacrolimus Products?
Existing tacrolimus products include immediate-release capsules and solutions, as well as extended-release formulations.
- Immediate-Release Formulations: These are susceptible to significant inter-patient variability due to factors like food intake and gastrointestinal motility. Patents like 10,973,795 aim to overcome this by controlling the API's physical properties.
- Extended-Release Formulations: These aim to provide more consistent drug levels over time. Patent 10,973,795's focus on particle size and specific excipients may offer a different approach to achieving consistent absorption, potentially with a different pharmacokinetic profile (e.g., faster achievement of therapeutic levels, or a distinct Cmax profile).
What is the Market Significance for Tacrolimus?
Tacrolimus is a widely prescribed immunosuppressant used in organ transplantation and for treating various autoimmune diseases, including atopic dermatitis and psoriasis. The global market for tacrolimus is substantial and continues to grow, driven by:
- Increasing Organ Transplants: A rising number of transplant procedures globally.
- Growing Incidence of Autoimmune Diseases: Higher prevalence of conditions treated with immunosuppressants.
- Advancements in Formulations: Development of more convenient and effective delivery systems.
The market is highly competitive, with both branded and generic products. The introduction of novel, patent-protected formulations can shift market dynamics by offering perceived clinical advantages or creating new intellectual property barriers.
What are the Potential Business Implications?
For pharmaceutical companies, understanding patents like 10,973,795 is critical for:
- R&D Strategy: Informing the development of new formulations that avoid infringement or create defensible intellectual property.
- Market Entry Planning: Assessing the freedom-to-operate for generic versions and identifying potential exclusivity windows.
- Licensing and Partnerships: Evaluating opportunities for in-licensing or out-licensing of tacrolimus-related technologies.
- Investment Decisions: Gauging the competitive landscape and future revenue potential for tacrolimus-based products.
The specific claims of patent 10,973,795, focusing on particle size and excipient combinations, suggest a strategic effort to improve upon existing tacrolimus delivery and potentially secure market advantages in a competitive therapeutic area.
Key Takeaways
U.S. Patent 10,973,795 protects specific tacrolimus pharmaceutical compositions and methods of treatment, focusing on controlled particle size (D90 ≤ 500 nm, D50 ≤ 200 nm) and combinations of hydrophilic polymers and hydrophobic excipients. These formulations aim to improve tacrolimus bioavailability and reduce inter-patient variability. The patent is an example of a formulation-based intellectual property strategy in the competitive tacrolimus market, which is driven by organ transplantation and autoimmune disease treatment. Companies developing or marketing tacrolimus products must consider this patent to ensure freedom to operate and to inform R&D and market strategies.
Frequently Asked Questions
-
When does U.S. Patent 10,973,795 expire?
U.S. Patent 10,973,795 was granted on April 13, 2021. U.S. patents generally have a term of 20 years from the filing date. Assuming a typical filing date relative to grant, the patent is expected to expire around 2037-2041, though specific extensions or maintenance fees could alter this. [1]
-
What specific diseases are covered by the method of treatment claims?
The method of treatment claims broadly cover "immune-mediated diseases." This includes, but is not limited to, conditions treated with immunosuppressants such as organ transplant rejection, atopic dermatitis, psoriasis, rheumatoid arthritis, and inflammatory bowel diseases. [1]
-
Does this patent prevent the sale of all generic tacrolimus products?
No, this patent does not prevent the sale of all generic tacrolimus products. It specifically protects compositions and methods matching the defined claims, particularly regarding particle size and excipient combinations. Generic products that do not infringe these specific claims, or that are based on expired foundational patents, may still be legally marketed. [1]
-
What is the significance of the D90 and D50 particle size specifications?
The D90 and D50 values represent the particle size distribution. A D90 of 500 nm or less and a D50 of 200 nm or less indicate that the tacrolimus particles are engineered to be very small. Smaller particle sizes generally increase the surface area available for dissolution, which can lead to faster and more complete absorption of the drug in the body, thus improving bioavailability and reducing variability. [1]
-
Can a generic manufacturer develop a tacrolimus formulation that infringes this patent?
A generic manufacturer could develop a tacrolimus formulation that infringes this patent if its product contains tacrolimus with a D90 not exceeding approximately 500 nm and a D50 not exceeding approximately 200 nm, and is formulated with a hydrophilic polymer and a hydrophobic excipient, as claimed. Circumventing the patent requires developing a formulation that falls outside the scope of these claims or operating under a license. [1]
Citations
[1] Sandoz AG. (2021). U.S. Patent 10,973,795: Pharmaceutical compositions and methods. United States Patent and Trademark Office.
